SCHEMBL6154425

SCHEMBL6154425

COc1cc(NC2CCN(C)CC2)ccc1C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.50
EHMT1 Q9H9B1 1/20 0.50
FLT3 P36888 2/20 0.48
NTRK3 Q16288 1/20 0.48
NTRK2 Q16620 1/20 0.48
KIT P10721 1/20 0.46
POLB P06746 1/20 0.46
CDK1 P06493 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
JAK2 O60674 1/20 0.45
JAK1 P23458 1/20 0.45
JAK3 P52333 1/20 0.45
PARP15 Q460N3 1/20 0.44
PARP10 Q53GL7 1/20 0.44
EML4 Q9HC35 1/20 0.43
ALK Q9UM73 1/20 0.43
GAA P10253 2/20 0.43
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154337 0.88 MAPT (0.52) FLT3KITCDK1JAK2JAK3
SCHEMBL6154109 0.87 SMN1; SMN2 (0.62) SMN1; SMN2NPSR1ALDH1A1MAPT
SCHEMBL6155038 0.86 CDK1 (0.52) CDK1SMN1; SMN2JAK2JAK3GAA
SCHEMBL6154287 0.86 PARP15 (0.55) FLT3KITPOLBSMN1; SMN2NPSR1
SCHEMBL6153579 0.85 KIT (0.60) FLT3KITPARP15PARP10GAA
SCHEMBL6153345 0.85 KIT (0.60) FLT3KITPARP15PARP10GAA
SCHEMBL6153341 0.85 KIT (0.60) FLT3KITPARP15PARP10GAA
SCHEMBL6153322 0.84 FLT3 (0.47) FLT3KITSMN1; SMN2JAK2JAK1
SCHEMBL6154491 0.84 KIT (0.47) FLT3KITSMN1; SMN2NPSR1PARP15
SCHEMBL6153679 0.84 HTR4 (0.48) FLT3KITCDK1PARP15PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110835336-B Oxygen-containing heterocyclic substituted azole compound and application thereof 中国药科大学 2022-10-04 CN disclosed
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 EHMT2 1237/4885EHMT1 1412/4885FLT3 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.